TOBY KARYADI: Open Payments
NPI 1013170422 · GAITHERSBURG, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,193 in 58 payments from 16 companies in 2025. Trend: 2023 $946 · 2024 $1,435 · 2025 $1,193
Food & beverage: $1,193
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 16 | $238 |
| Novo Nordisk Inc | 10 | $238 |
| Lilly USA, LLC | 5 | $114 |
| AstraZeneca Pharmaceuticals LP | 5 | $110 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $83 |
| Exact Sciences Corporation | 3 | $70 |
| Abbott Laboratories | 3 | $66 |
| Merck Sharp & Dohme LLC | 3 | $59 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $40 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $35 |
Products named: QULIPTA, UBRELVY, JARDIANCE, MOUNJARO, Wegovy, Ozempic, FREESTYLE LIBRE 3, GARDASIL 9.
Industry payments across MD — which companies pay providers there.
